

#3

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Xin Lu
Application No. Currently unknown
Filed: Herewith
Confirmation No. Currently unknown
For: SCREENING METHOD
Examiner: Not yet assigned
Art Unit: Not yet assigned
Attorney Reference No. 5585-70602-01

COMMISSIONER FOR PATENTS
P.O. BOX 1450
ALEXANDRIA, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT
PURSUANT TO 37 C.F.R. § 1.97(b)(2)

Listed on the accompanying form PTO-1449 and enclosed herewith are several English-language documents. Applicant respectfully requests that these documents be listed as references cited on the issued patent.

Applicant filed this Information Disclosure Statement ("IDS") within three months of the date of entry of the national stage as set forth in § 1.491 in an international application. As a result, no fee should be required to file this IDS. However, if the Patent Office determines that a fee is required for Applicant to file this IDS, please charge any such fees, or credit overpayment, to Deposit Account No. 02-4550. A **duplicate** copy of this IDS is enclosed.

10/530450
JCOG Rec'd UPTO 06 APR 2005


WDN/SLR:dm 04/05/05 5585-70602-01 365808

Express Mail No. EV514612899US
Date of Deposit: April 6, 2005
PATENT

The filing of this IDS shall not be construed to be an admission that the information cited in the statement is, or is considered to be, prior art or otherwise material to patentability as defined in 37 C.F.R. §1.56.

Respectfully submitted,

KLARQUIST SPARKMAN, LLP

By 
Sheree Lynn Rybak, Ph.D.
Registration No. 47,913

One World Trade Center, Suite 1600
121 S.W. Salmon Street
Portland, Oregon 97204
Telephone: (503) 226-7391
Facsimile: (503) 228-9446

cc: Docketing

INFORMATION DISCLOSURE STATEMENT BY APPLICANT	Attorney Docket Number	5585-70602-01
	Application Number	10/530450
	Filing Date	
	First Named Inventor	Lu
	Art Unit	Not yet assigned
	Examiner Name	Not yet assigned

U.S. PATENT DOCUMENTS

Copies of U.S. Patent documents do not need to be provided, unless requested by the Patent and Trademark Office. For patents, provide the patent number and the issue date. For published U.S. applications, provide the publication number and the publication date. For unpublished pending patent applications, provide the application number and the filing date.

Examiner's Initials*	Cite No. (optional)	Number	Publication Date	Name of Applicant or Patentee

FOREIGN PATENT DOCUMENTS

Examiner's Initials*	Cite No. (optional)	Country	Number	Publication Date	Name of Applicant or Patentee
		WIPO	WO 99/15657 A2	01.04.1999	Curagen Corporation
		WIPO	WO 02/12325 A2	14.02.2002	Ludwig Institute for Cancer Research
		WIPO	WO 03/031571 A2	17.04.2003	Curagen Corporation

OTHER DOCUMENTS

Examiner's Initials*	Cite No. (optional)	
		Samuels-Lev et al., "ASPP Proteins Specifically Stimulate the Apoptotic Function of p53," <i>Mol. Cell</i> 8:781-794 (2001).
		Tan et al., "Immunohistochemical Study of p53-Associated Proteins in Rat Brain Following Lithium-Pilocarpine Status Epilepticus," <i>Brain Res.</i> 929:129-138 (2002).

EXAMINER SIGNATURE:	DATE CONSIDERED:
<p>* Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.</p>	